NeVap

NeVap Inc is a biotechnology and healthcare startup founded in 2014. The company is dedicated to addressing critical unmet clinical needs with innovative medical devices designed to reduce critical care costs and save lives. NeVap's mission is to mitigate Ventilator-Associated Pneumonia, a prevalent, serious, and costly hospital-acquired infection in modern healthcare. They have developed the NeVap Aspire Subglottic Suction Endotracheal Tube, an FDA and CE Mark cleared device that offers infection protection in the operating room, intensive care unit, and emergency department. The company raised a $1.00M Seed Round investment on 30 June 2015. While the investors for the last round are not disclosed, the innovative approach of NeVap in addressing a critical healthcare challenge presents a promising opportunity. The focus on reducing healthcare costs and improving patient outcomes aligns with the current trends in the healthcare industry, making NeVap an intriguing prospect for venture capital investment.